Specialist-led community-based cardio-kidney-metabolic-pulmonary care in high risk individuals: multi-centre pragmatic prospective randomised open label blinded endpoint trial

Clicks: 11
ID: 331684
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #63 of 80 articles by views in European Heart Journal Open

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background and Aims Pharmacological therapies that treat cardiovascular, kidney, metabolic and pulmonary (CKMP) risk factors reduce the risk of major adverse cardiovascular events, but community-dwelling individuals may not receive all treatments to which they are eligible from non-specialists. This trial investigated if specialist-led care in the community increases the utilisation of CKMP pharmacological interventions compared with usual care. Methods This pragmatic prospective randomised open label blinded endpoint trial included community-dwelling high risk adults aged ≥30 years from 15 primary care sites in England. Participants were randomised 1:1 to an intervention of two clinic appointments (at baseline and approximately 3 months) with a cardiology specialist at their primary care site to review and optimise CKMP risk factors in accordance with UK guidelines, or usual care. The primary outcome was the proportion of participants with initiation and/or increase in the dose of guideline-directed CKMP pharmacological therapies at 6 months after date of randomisation. Results Between March 2025 and July 2025, 138 participants were randomised (68 intervention, 70 control); the median age was 76.6 years, 52.9% were women. At 6 months after randomisation, in the intervention arm 42 of 68 (61.8%) patients received a CKMP pharmacological intervention compared with 16 of 70 patients (22.9%) in the control arm (odds ratio 5.4, 95% CI 2.5 to 12.3, p < 0.0001, absolute risk difference 38.9%, 95% CI 23.7% to 54.1%). Conclusions Specialist-led care in the community for high risk individuals increased the use of pharmacological interventions for CKMP risk factors compared to usual care.
Reference Key
openalex_W7220869078 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ramesh Nadarajah, Ali Wahab, Ben Hurdus, Carl Simela, Tobin Joseph, Catherine Revnolds, Sheena Bennet, Mohammad Haris, Louise Clark, Christopher S. Hayward, Jing Xin Kang, Jianhua Wu, Chris P Gale
Are you one of these authors? Claim your profile
Journal European Heart Journal Open
Year 2026
DOI
10.1093/ehjopen/oeag169
URL
https://academic.oup.com/ehjopen/advance-article-pdf/doi/10.1093/ehjopen/oeag169/71640584/oeag169.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.